Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 21 studies | 54% ± 13% | |
peripheral blood | 20 studies | 59% ± 15% | |
brain | 20 studies | 48% ± 17% | |
eye | 12 studies | 53% ± 18% | |
intestine | 11 studies | 44% ± 16% | |
kidney | 11 studies | 46% ± 12% | |
heart | 7 studies | 40% ± 14% | |
liver | 7 studies | 55% ± 17% | |
bone marrow | 6 studies | 43% ± 21% | |
lymph node | 6 studies | 53% ± 16% | |
pancreas | 5 studies | 57% ± 22% | |
uterus | 5 studies | 61% ± 16% | |
adipose | 5 studies | 53% ± 25% | |
prostate | 5 studies | 36% ± 10% | |
breast | 5 studies | 48% ± 16% | |
placenta | 4 studies | 47% ± 13% | |
esophagus | 4 studies | 38% ± 25% | |
skin | 4 studies | 38% ± 13% | |
adrenal gland | 3 studies | 50% ± 12% | |
stomach | 3 studies | 41% ± 21% | |
thymus | 3 studies | 65% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 18311.57 | 21 / 21 | 100% | 50.42 | 504 / 504 |
esophagus | 100% | 18032.37 | 1445 / 1445 | 100% | 100.22 | 183 / 183 |
ovary | 100% | 20889.43 | 180 / 180 | 100% | 50.13 | 430 / 430 |
prostate | 100% | 16625.21 | 245 / 245 | 100% | 64.15 | 502 / 502 |
breast | 100% | 19178.18 | 459 / 459 | 100% | 82.99 | 1117 / 1118 |
thymus | 100% | 21317.18 | 653 / 653 | 100% | 63.51 | 604 / 605 |
uterus | 100% | 21163.98 | 170 / 170 | 100% | 52.93 | 458 / 459 |
lung | 100% | 19330.43 | 578 / 578 | 100% | 60.39 | 1152 / 1155 |
intestine | 100% | 18768.09 | 966 / 966 | 100% | 51.95 | 525 / 527 |
stomach | 100% | 15716.63 | 359 / 359 | 99% | 64.15 | 284 / 286 |
brain | 99% | 8773.04 | 2611 / 2642 | 100% | 68.25 | 705 / 705 |
skin | 100% | 17239.54 | 1809 / 1809 | 99% | 63.35 | 466 / 472 |
pancreas | 100% | 9632.57 | 327 / 328 | 99% | 50.56 | 176 / 178 |
kidney | 100% | 11124.75 | 89 / 89 | 98% | 51.24 | 879 / 901 |
adrenal gland | 100% | 17078.02 | 258 / 258 | 96% | 44.33 | 220 / 230 |
liver | 100% | 7708.00 | 226 / 226 | 89% | 24.67 | 360 / 406 |
adipose | 100% | 18799.61 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 19570.46 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 57.54 | 29 / 29 |
muscle | 100% | 13281.47 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 21227.20 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 62.69 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 20.60 | 1 / 1 |
heart | 99% | 11051.82 | 851 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 34.61 | 74 / 80 |
peripheral blood | 84% | 10031.41 | 779 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043484 | Biological process | regulation of RNA splicing |
GO_0008380 | Biological process | RNA splicing |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0000281 | Biological process | mitotic cytokinesis |
GO_0048024 | Biological process | regulation of mRNA splicing, via spliceosome |
GO_0006397 | Biological process | mRNA processing |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0000226 | Biological process | microtubule cytoskeleton organization |
GO_0016607 | Cellular component | nuclear speck |
GO_0003677 | Molecular function | DNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | SON |
Protein name | SON protein Protein SON (Bax antagonist selected in saccharomyces 1) (BASS1) (Negative regulatory element-binding protein) (NRE-binding protein) (Protein DBP-5) (SON3) SON DNA and RNA binding protein SON protein SON3 |
Synonyms | C21orf50 HSPC310 NREBP DBP5 HSPC312 KIAA1019 |
Description | FUNCTION: RNA-binding protein that acts as a mRNA splicing cofactor by promoting efficient splicing of transcripts that possess weak splice sites. Specifically promotes splicing of many cell-cycle and DNA-repair transcripts that possess weak splice sites, such as TUBG1, KATNB1, TUBGCP2, AURKB, PCNT, AKT1, RAD23A, and FANCG. Probably acts by facilitating the interaction between Serine/arginine-rich proteins such as SRSF2 and the RNA polymerase II. Also binds to DNA; binds to the consensus DNA sequence: 5'-GA[GT]AN[CG][AG]CC-3'. May indirectly repress hepatitis B virus (HBV) core promoter activity and transcription of HBV genes and production of HBV virions. Essential for correct RNA splicing of multiple genes critical for brain development, neuronal migration and metabolism, including TUBG1, FLNA, PNKP, WDR62, PSMD3, PCK2, PFKL, IDH2, and ACY1 . . |
Accessions | H7C2G8 ENST00000457208.5 ENST00000704334.1 H7C257 A0A8Q3SI10 A0JLP4 ENST00000421541.1 H7C1S4 A0A994J4Y9 J3QSZ5 H7C1M2 ENST00000356577.10 [P18583-1] Q3SWV4 ENST00000381679.8 [P18583-6] P18583 Q3YL85 ENST00000429093.6 ENST00000300278.8 [P18583-3] ENST00000695559.1 ENST00000436227.5 ENST00000455528.5 [P18583-4] ENST00000381692.6 |